Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.

Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, Palmaira RLD, Javed AA, Huynh JC, Johnson M, Arora K, Robine N, Shah M, Sanghvi R, Goetz AB, Lowder CY, Martello L, Driehuis E, LeComte N, Askan G, Iacobuzio-Donahue CA, Clevers H, Wood LD, Hruban RH, Thompson E, Aguirre AJ, Wolpin BM, Sasson A, Kim J, Wu M, Bucobo JC, Allen P, Sejpal DV, Nealon W, Sullivan JD, Winter JM, Gimotty PA, Grem JL, DiMaio DJ, Buscaglia JM, Grandgenett PM, Brody JR, Hollingsworth MA, O'Kane GM, Notta F, Kim E, Crawford JM, Devoe C, Ocean A, Wolfgang CL, Yu KH, Li E, Vakoc CR, Hubert B, Fischer SE, Wilson JM, Moffitt R, Knox J, Krasnitz A, Gallinger S, Tuveson DA.

Cancer Discov. 2018 Sep;8(9):1112-1129. doi: 10.1158/2159-8290.CD-18-0349. Epub 2018 May 31.

PMID:
29853643
2.

Soils and Seeds That Initiate Pancreatic Cancer Metastasis.

Vakoc CR, Tuveson DA.

Cancer Discov. 2017 Oct;7(10):1067-1068. doi: 10.1158/2159-8290.CD-17-0887.

PMID:
28974531
3.

Transcriptional Regulation by Nrf2.

Tonelli C, Chio IIC, Tuveson DA.

Antioxid Redox Signal. 2017 Oct 20. doi: 10.1089/ars.2017.7342. [Epub ahead of print]

PMID:
28899199
4.

Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma.

Feigin ME, Garvin T, Bailey P, Waddell N, Chang DK, Kelley DR, Shuai S, Gallinger S, McPherson JD, Grimmond SM, Khurana E, Stein LD, Biankin AV, Schatz MC, Tuveson DA.

Nat Genet. 2017 Jun;49(6):825-833. doi: 10.1038/ng.3861. Epub 2017 May 8.

5.

ROS in Cancer: The Burning Question.

Chio IIC, Tuveson DA.

Trends Mol Med. 2017 May;23(5):411-429. doi: 10.1016/j.molmed.2017.03.004. Epub 2017 Apr 17. Review.

6.

Quid pro Quo: A Tumor is Not Alone.

Sacristán C, Tuveson DA.

Trends Mol Med. 2017 May;23(5):375-376. doi: 10.1016/j.molmed.2017.03.007. Epub 2017 Apr 10. No abstract available.

PMID:
28408271
7.

Challenges and Opportunities in Modeling Pancreatic Cancer.

Feigin ME, Tuveson DA.

Cold Spring Harb Symp Quant Biol. 2016;81:231-235. doi: 10.1101/sqb.2016.81.031104. Epub 2017 Mar 13. Review.

PMID:
28289164
8.

Untangling the genetics from the epigenetics in pancreatic cancer metastasis.

Vakoc CR, Tuveson DA.

Nat Genet. 2017 Feb 24;49(3):323-324. doi: 10.1038/ng.3798.

PMID:
28232730
9.

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.

Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II, Hwang CI, Tiriac H, Baker LA, Engle DD, Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, Tuveson DA.

J Exp Med. 2017 Mar 6;214(3):579-596. doi: 10.1084/jem.20162024. Epub 2017 Feb 23.

10.

Cancer: Double trouble for tumours.

Biffi G, Tuveson DA.

Nature. 2017 Feb 2;542(7639):34-35. doi: 10.1038/nature21117. Epub 2017 Jan 18. No abstract available.

PMID:
28099410
11.

ROS in translation: Chink in the armor.

Chio II, Tuveson DA.

Cell Cycle. 2017 Feb 16;16(4):297-298. doi: 10.1080/15384101.2016.1232087. Epub 2016 Sep 16. No abstract available.

12.

NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer.

Chio IIC, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera K, Palm W, Wilson J, Sangar V, Hao Y, Öhlund D, Wright K, Filippini D, Lee EJ, Da Silva B, Schoepfer C, Wilkinson JE, Buscaglia JM, DeNicola GM, Tiriac H, Hammell M, Crawford HC, Schmidt EE, Thompson CB, Pappin DJ, Sonenberg N, Tuveson DA.

Cell. 2016 Aug 11;166(4):963-976. doi: 10.1016/j.cell.2016.06.056. Epub 2016 Jul 28.

13.

Modeling pancreatic cancer with organoids.

Baker LA, Tiriac H, Clevers H, Tuveson DA.

Trends Cancer. 2016 Apr;2(4):176-190.

14.

Preclinical models of pancreatic ductal adenocarcinoma.

Hwang CI, Boj SF, Clevers H, Tuveson DA.

J Pathol. 2016 Jan;238(2):197-204. doi: 10.1002/path.4651. Epub 2015 Nov 14. Review.

15.

Organoid models of human and mouse ductal pancreatic cancer.

Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Öhlund D, Handly-Santana A, Ardito-Abraham CM, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov GN, Delcuze B, Creighton B, Wright K, Park Y, Morsink FH, Molenaar IQ, Borel Rinkes IH, Cuppen E, Hao Y, Jin Y, Nijman IJ, Iacobuzio-Donahue C, Leach SD, Pappin DJ, Hammell M, Klimstra DS, Basturk O, Hruban RH, Offerhaus GJ, Vries RG, Clevers H, Tuveson DA.

Cell. 2015 Jan 15;160(1-2):324-38. doi: 10.1016/j.cell.2014.12.021. Epub 2014 Dec 31.

16.

The RAS and YAP1 dance, who is leading?

Corbo V, Ponz-Sarvise M, Tuveson DA.

EMBO J. 2014 Nov 3;33(21):2437-8. doi: 10.15252/embj.201490014. Epub 2014 Sep 25. No abstract available.

17.

The promise and perils of antioxidants for cancer patients.

Chandel NS, Tuveson DA.

N Engl J Med. 2014 Jul 10;371(2):177-8. doi: 10.1056/NEJMcibr1405701. No abstract available.

PMID:
25006725
18.

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.

Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA.

Gut. 2014 Jun;63(6):974-83. doi: 10.1136/gutjnl-2013-305559. Epub 2013 Sep 25.

19.

CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.

Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilarsky C, Jodrell DI, Spong SM, Tuveson DA.

Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12325-30. doi: 10.1073/pnas.1300415110. Epub 2013 Jul 8.

20.

The pancreas cancer microenvironment.

Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA.

Clin Cancer Res. 2012 Aug 15;18(16):4266-76. doi: 10.1158/1078-0432.CCR-11-3114. Review.

Supplemental Content

Loading ...
Support Center